8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Apr 28, 2026·SEC
Material company update
Feb 26, 2026·SEC
Janux Therapeutics, Inc.(JANX)Earnings, Financials & Key Ratios
JANX•NASDAQ
Price updated Jun 19, 2026
AboutJanux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.Show more
- Revenue$10M-5.6%
- EBITDA-$156M-60.8%
- Net Income-$114M-64.7%
- EPS (Diluted)-1.83-43.0%
- Gross Margin79.71%-1.0%
- EBITDA Margin-1556.38%-70.3%
- Operating Margin-1576.67%-68.9%
- Net Margin-1136.25%-74.4%
- ROE-11.48%-13.7%
JANX Key Insights
Janux Therapeutics, Inc. (JANX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Trading at only 0.9x book value
✗Weaknesses
- ✗Profits declining 75.7% over 5 years
- ✗Weak Piotroski F-Score: 1/9
- ✗Negative free cash flow
- ✗Shares diluted 15.3% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when JANX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
JANX Price & Volume
Janux Therapeutics, Inc. (JANX) stock price & volume — 10-year historical chart
Loading chart...
JANX Growth Metrics
Janux Therapeutics, Inc. (JANX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years5.11%
TTM131.5%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-47.25%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-35.29%
Return on Capital
10 Years-32.11%
5 Years-17.22%
3 Years-16.66%
Last Year-15.56%
JANX Recent Earnings
Janux Therapeutics, Inc. (JANX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (83%)●Beat Revenue 6/12 qtrs (75%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.39+25.0%
$0.52
Rev
$4M-14.3%
$4M
Q1 2026
Feb 26, 2026Metric
Actual
Est
EPS
$0.51+21.5%
$0.65
Rev
$8M+9356.0%
$83,333
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.39+35.0%
$0.60
Rev
$10M
—
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.55-14.6%
$0.48
Rev
—
$300,000
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.39vs $0.52+25.0% | $4Mvs $4M-14.3% |
| Q1 2026 | Feb 26, 2026 | $0.51vs $0.65+21.5% | $8Mvs $83,333+9356.0% |
| Q4 2025 | Nov 6, 2025 | $0.39vs $0.60+35.0% | $10M |
| Q3 2025 | Aug 7, 2025 | $0.55vs $0.48-14.6% | —vs $300,000 |
Based on last 12 quarters of dataView full earnings history →
JANX Peer Comparison
Janux Therapeutics, Inc. (JANX) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 | |||
 KYMR | 7.38B | 90.43 | -24.51 | -16.72% | -6.12% | -25.02% | 0.05 | |
 RCUS | 2.45B | 24.31 | -7.39 | -4.26% | -156.36% | -68.97% | 0.16 | |
 TNGX | 3.25B | 27.97 | -32.15 | 48.29% | -188.15% | -41.54% | 0.10 | |
 RVMD | 34.65B | 162.99 | -27.39 | -83.22% | 0.10 | |||
 XNCR | 927M | 12.64 | -10.19 | 13.65% | -185.71% | -28.77% | 0.30 | |
 MGNX | 262.52M | 4.13 | -3.50 | 0.78% | -44.79% | -147.8% | 1.92 | |
 AGEN | 124.93M | 3.00 | -882.35 | 10.37% | 52.16% |
Compare JANX vs Peers
Janux Therapeutics, Inc. (JANX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
JANX Income Statement
Janux Therapeutics, Inc. (JANX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 3.64M | 8.61M | 8.08M | 10.59M | 10M | 21.61M |
Revenue Growth % | - | - | - | 136.79% | -6.14% | 30.99% | -5.55% | 131.5% |
Cost of Goods Sold | 6K | 13K | 0 | 841K | 1.96M | 2.06M | 2.03M | 9.91M |
COGS % of Revenue | - | - | - | 9.77% | 24.19% | 19.46% | 20.29% | - |
Gross Profit | -6K▲ 0% | -13K▼ 116.7% | 3.64M▲ 28076.9% | 7.77M▲ 113.7% | 6.13M▼ 21.1% | 8.53M▲ 39.2% | 7.97M▼ 6.5% | 11.7M▲ 0% |
Gross Margin % | - | - | 100% | 90.23% | 75.81% | 80.54% | 79.71% | 54.15% |
Gross Profit Growth % | - | -116.67% | 28076.92% | 113.67% | -21.14% | 39.16% | -6.53% | - |
Operating Expenses | 3.77M | 4.83M | 36.57M | 74.86M | 79.11M | 107.38M | 165.64M | 168.69M |
OpEx % of Revenue | - | - | 1005.39% | 869.28% | 978.68% | 1014.12% | 1656.38% | - |
Selling, General & Admin | 772K | 1.79M | 10.33M | 22.26M | 26.14M | 41.05M | 41.77M | 42.56M |
SG&A % of Revenue | - | - | 284% | 258.5% | 323.39% | 387.67% | 417.71% | - |
Research & Development | 3M | 3.04M | 26.24M | 53.44M | 54.92M | 68.39M | 125.9M | 127.65M |
R&D % of Revenue | - | - | 721.39% | 620.54% | 679.48% | 645.9% | 1258.96% | - |
Other Operating Expenses | 0 | 0 | 0 | -841K | -1.96M | -2.06M | -2.03M | -1.47M |
Operating Income | -3.77M▲ 0% | -4.84M▼ 28.4% | -32.93M▼ 579.9% | -67.09M▼ 103.7% | -72.98M▼ 8.8% | -98.85M▼ 35.4% | -157.67M▼ 59.5% | -156.98M▲ 0% |
Operating Margin % | - | - | -905.39% | -779.04% | -902.87% | -933.58% | -1576.67% | -726.34% |
Operating Income Growth % | - | -28.43% | -579.93% | -103.74% | -8.78% | -35.45% | -59.51% | - |
EBITDA | -3.77M | -4.83M | -32.82M | -66.25M | -71.02M | -96.79M | -155.64M | -154.95M |
EBITDA Margin % | - | - | -902.28% | -769.28% | -878.68% | -914.12% | -1556.38% | -716.94% |
EBITDA Growth % | - | -28.29% | -579.42% | -101.88% | -7.21% | -36.27% | -60.8% | -38.93% |
D&A (Non-Cash Add-back) | 6K | 13K | 113K | 841K | 1.96M | 2.06M | 2.03M | 2.03M |
EBIT | -3.77M | -6.58M | -32.93M | -67.09M | -72.98M | -98.85M | -113.63M | -135.59M |
Net Interest Income | 0 | 0 | 257K | 4.03M | 14.69M | 29.85M | 44.04M | 66.09M |
Interest Income | 233K | 206K | 257K | 4.03M | 14.69M | 29.85M | 44.04M | 66.09M |
Interest Expense | 233K | 206K | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | -233K | -1.94M | 257K | 4.03M | 14.69M | 29.85M | 44.04M | 42.51M |
Pretax Income | -4M▲ 0% | -6.78M▼ 69.4% | -32.67M▼ 381.6% | -63.06M▼ 93.0% | -58.29M▲ 7.6% | -68.99M▼ 18.4% | -113.63M▼ 64.7% | -114.48M▲ 0% |
Pretax Margin % | - | - | -898.32% | -732.22% | -721.18% | -651.62% | -1136.25% | -529.67% |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -4.24M▲ 0% | -6.78M▼ 60.1% | -32.67M▼ 381.6% | -63.06M▼ 93.0% | -58.29M▲ 7.6% | -68.99M▼ 18.4% | -113.63M▼ 64.7% | -114.48M▲ 0% |
Net Margin % | - | - | -898.32% | -732.22% | -721.18% | -651.62% | -1136.25% | -529.67% |
Net Income Growth % | - | -60.11% | -381.6% | -93.01% | 7.56% | -18.36% | -64.69% | -47.25% |
Net Income (Continuing) | -4M | -6.78M | -32.67M | -63.06M | -58.29M | -68.99M | -113.63M | -114.48M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.10▲ 0% | -0.16▼ 60.0% | -0.79▼ 393.8% | -1.52▼ 92.4% | -1.32▲ 13.2% | -1.28▲ 3.0% | -1.83▼ 43.0% | -1.83▲ 0% |
EPS Growth % | - | -60% | -393.75% | -92.41% | 13.16% | 3.03% | -42.97% | -35.29% |
EPS (Basic) | -0.10 | -0.16 | -0.79 | -1.52 | -1.32 | -1.28 | -1.83 | - |
Diluted Shares Outstanding | 41.61M | 41.61M | 41.24M | 41.47M | 44.02M | 53.75M | 61.97M | 62.67M |
Basic Shares Outstanding | 41.61M | 41.61M | 41.24M | 41.47M | 44.02M | 53.75M | 61.97M | 62.67M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - |
JANX Balance Sheet
Janux Therapeutics, Inc. (JANX) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Total Current Assets | 658K | 16.06M | 377.02M | 332.44M | 349.24M | 1.03B | 975.89M | 1B |
Cash & Short-Term Investments | 658K | 7.81M | 374.96M | 327.02M | 344.03M | 1.03B | 966.57M | 956.39M |
Cash Only | 658K | 7.81M | 35.58M | 51.43M | 19.2M | 430.61M | 52.33M | 51.83M |
Short-Term Investments | 0 | 0 | 339.38M | 275.59M | 324.82M | 594.57M | 914.23M | 904.56M |
Accounts Receivable | 0 | 8M | 0 | 700K | 0 | 5.38M | 6.43M | 42.46M |
Days Sales Outstanding | - | - | - | 29.67 | - | 185.5 | 234.62 | 257.11 |
Inventory | 0 | 0 | 0 | -700K | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 0 | 5.42M | 5.21M | 0 | 0 | 0 |
Total Non-Current Assets | 21K | 155K | 2.81M | 31.57M | 31.17M | 27.85M | 31.64M | 26.18M |
Property, Plant & Equipment | 21K | 155K | 1.6M | 29.36M | 27.84M | 24.15M | 22.25M | 21.42M |
Fixed Asset Turnover | - | - | 2.28x | 0.29x | 0.29x | 0.44x | 0.45x | 0.96x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 816K | 0 | 0 | 816K | 2.45M |
Other Non-Current Assets | 0 | 0 | 1.21M | 1.39M | 3.33M | 3.7M | 2.61M | 4.76M |
Total Assets | 679K▲ 0% | 16.22M▲ 2288.4% | 379.82M▲ 2242.1% | 364.01M▼ 4.2% | 380.41M▲ 4.5% | 1.06B▲ 179.0% | 1.01B▼ 5.1% | 1.03B▲ 0% |
Asset Turnover | - | - | 0.01x | 0.02x | 0.02x | 0.01x | 0.01x | 0.02x |
Asset Growth % | - | 2288.37% | 2242.13% | -4.16% | 4.5% | 179.05% | -5.09% | 89.5% |
Total Current Liabilities | 4.63M | 3.18M | 12.8M | 16.51M | 13.03M | 17.46M | 25M | 58.91M |
Accounts Payable | 267K | 428K | 2.46M | 2.16M | 2.42M | 4.03M | 4.97M | 3.38M |
Days Payables Outstanding | 16.24K | 12.02K | - | 937.02 | 452.56 | 713.34 | 894.24 | 140.13 |
Short-Term Debt | 4M | 0 | 0 | 0 | 0 | 0 | 2.39M | 2.47M |
Deferred Revenue (Current) | 0 | 1.95M | 5.16M | 5.41M | 1.71M | 0 | 0 | 37.59M |
Other Current Liabilities | 82K | 338K | 2.37M | 5.51M | 3.3M | 11.68M | 13.04M | 15.48M |
Current Ratio | 0.14x | 5.05x | 29.46x | 20.14x | 26.80x | 59.21x | 39.04x | 17.01x |
Quick Ratio | 0.14x | 5.05x | 29.46x | 20.18x | 26.80x | 59.21x | 39.04x | 17.01x |
Cash Conversion Cycle | - | - | - | - | - | - | - | 116.97 |
Total Non-Current Liabilities | 4M | 27.67M | 700K | 26.76M | 23.02M | 21.28M | 25.7M | 27.77M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 24.54M | 23.02M | 21.28M | 19.75M | 79.54M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 5.96M | 5.96M |
Other Non-Current Liabilities | 4M | 21.62M | 0 | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 8.62M | 30.86M | 13.5M | 43.27M | 36.06M | 38.73M | 50.7M | 86.69M |
Total Debt | 4M | 0 | 194K | 25.3M | 24.54M | 23.02M | 22.14M | 21.57M |
Net Debt | 3.34M | -7.81M | -35.39M | -26.12M | 5.34M | -407.58M | -30.2M | -30.26M |
Debt / Equity | - | - | 0.00x | 0.08x | 0.07x | 0.02x | 0.02x | 0.02x |
Debt / EBITDA | - | - | - | - | - | - | - | -0.14x |
Net Debt / EBITDA | - | - | - | - | - | - | - | 0.20x |
Interest Coverage | -16.18x | -31.93x | - | - | - | - | - | - |
Total Equity | -7.94M▲ 0% | -14.64M▼ 84.3% | 366.33M▲ 2602.6% | 320.74M▼ 12.4% | 344.35M▲ 7.4% | 1.02B▲ 197.0% | 956.82M▼ 6.4% | 941.53M▲ 0% |
Equity Growth % | - | -84.26% | 2602.58% | -12.44% | 7.36% | 197.02% | -6.45% | 85.99% |
Book Value per Share | -0.19 | -0.35 | 8.88 | 7.73 | 7.82 | 19.03 | 15.44 | 15.02 |
Total Shareholders' Equity | -7.94M | -14.64M | 366.33M | 320.74M | 344.35M | 1.02B | 956.82M | 941.53M |
Common Stock | 1K | 1K | 41K | 42K | 46K | 59K | 60K | 60K |
Retained Earnings | -7.96M | -14.74M | -47.41M | -110.47M | -168.76M | -237.76M | -351.38M | -375.74M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | -270K | -1.53M | 665K | 2.16M | 4.32M | 576K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
JANX Cash Flow Statement
Janux Therapeutics, Inc. (JANX) cash flow — operating, investing & free cash flow history
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Cash from Operations | -3.83M | -4.37M | -16.98M | -42.92M | -50.58M | -43.81M | -82.23M | -77.55M |
Operating CF Margin % | - | - | -466.76% | -498.4% | -625.7% | -413.81% | -822.35% | - |
Operating CF Growth % | - | -14.13% | -288.56% | -152.84% | -17.83% | 13.37% | -87.69% | -657% |
Net Income | -4M | -6.78M | -32.67M | -63.06M | -58.29M | -68.99M | -113.63M | -114.48M |
Depreciation & Amortization | 6K | 13K | 113K | 841K | 1.96M | 2.06M | 2.03M | 1.51M |
Stock-Based Compensation | 6K | 72K | 6.91M | 17.2M | 20M | 33.02M | 40.22M | 29.52M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 233K | 1.94M | -169K | -2.18M | -7.69M | -10.59M | -17.57M | -6.24M |
Working Capital Changes | -69K | 389K | 8.84M | 4.28M | -6.55M | 685K | 6.71M | 12.14M |
Change in Receivables | 0 | -8M | 8M | 0 | 0 | 0 | 0 | -35M |
Change in Inventory | 0 | 0 | 831K | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 4K | 14K | 2.14M | -294K | 277K | 1.58M | 977K | 1M |
Cash from Investing | 0 | 0 | -340.96M | 58.27M | -41.19M | -258.02M | -300.98M | 47.7M |
Capital Expenditures | 0 | 0 | -1.48M | -6.45M | -1.85M | -359K | -1.04M | -945K |
CapEx % of Revenue | - | - | 40.75% | 74.84% | 22.89% | 3.39% | 10.43% | 4.37% |
Acquisitions | 0 | 0 | 339.48M | -64.71M | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | -339.48M | 64.71M | 0 | 0 | 0 | 0 |
Cash from Financing | 4M | 11.52M | 386.52M | 500K | 59.55M | 713.24M | 4.95M | 7.94M |
Debt Issued (Net) | 4M | 2.5M | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 0 | 8.95M | 384.71M | 500K | 56.53M | 698.27M | 4.95M | 7.94M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | -347K | 0 |
Other Financing | 0 | 70K | 1.81M | 0 | 3.02M | 14.97M | 0 | 0 |
Net Change in Cash | 172K▲ 0% | 7.16M▲ 4059.9% | 28.59M▲ 299.5% | 15.84M▼ 44.6% | -32.22M▼ 303.4% | 411.4M▲ 1376.8% | -378.27M▼ 191.9% | -21.91M▲ 0% |
Free Cash Flow | -3.83M▲ 0% | -4.37M▼ 14.1% | -18.46M▼ 322.5% | -49.37M▼ 167.5% | -52.42M▼ 6.2% | -44.17M▲ 15.7% | -83.28M▼ 88.5% | -78.49M▲ 0% |
FCF Margin % | - | - | -507.51% | -573.24% | -648.58% | -417.2% | -832.78% | -363.17% |
FCF Growth % | - | -14.13% | -322.48% | -167.46% | -6.19% | 15.74% | -88.53% | -68.68% |
FCF per Share | -0.09 | -0.10 | -0.45 | -1.19 | -1.19 | -0.82 | -1.34 | -1.25 |
FCF Conversion (FCF/Net Income) | 0.90x | 0.64x | 0.52x | 0.68x | 0.87x | 0.64x | 0.72x | 0.69x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
JANX Key Ratios
Janux Therapeutics, Inc. (JANX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | -18.58% | -18.36% | -17.53% | -10.09% | -11.48% | -11.85% |
Return on Invested Capital (ROIC) | - | -16.01% | -16.09% | -16.99% | -15.37% | -15.34% | -12.56% |
Gross Margin | - | 100% | 90.23% | 75.81% | 80.54% | 79.71% | 54.15% |
Net Margin | - | -898.32% | -732.22% | -721.18% | -651.62% | -1136.25% | -529.67% |
Debt / Equity | - | 0.00x | 0.08x | 0.07x | 0.02x | 0.02x | 0.02x |
Interest Coverage | -31.93x | - | - | - | - | - | - |
FCF Conversion | 0.64x | 0.52x | 0.68x | 0.87x | 0.64x | 0.72x | 0.69x |
Revenue Growth | - | - | 136.79% | -6.14% | 30.99% | -5.55% | 131.5% |
Related:JANX Dividend History·JANX Revenue History·JANX Price History·JANX P/E History·JANX Financial Ratios·JANX Institutional Holders
JANX SEC Filings & Documents
Janux Therapeutics, Inc. (JANX) SEC filings — annual & quarterly reports (10-K, 10-Q)
JANX Frequently Asked Questions
Janux Therapeutics, Inc. (JANX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Janux Therapeutics, Inc. (JANX) reported $21.6M in revenue for fiscal year 2025.
Janux Therapeutics, Inc. (JANX) saw revenue decline by 5.6% over the past year.
Janux Therapeutics, Inc. (JANX) reported a net loss of $114.5M for fiscal year 2025.
Dividend & Returns
Janux Therapeutics, Inc. (JANX) has a return on equity (ROE) of -11.5%. Negative ROE indicates the company is unprofitable.
Janux Therapeutics, Inc. (JANX) had negative free cash flow of $78.5M in fiscal year 2025, likely due to heavy capital investments.